None listed
Conditions
Brief summary
Insulin therapy for people with Type 1 Diabetes has the risk of hypoglycaemia when insulin administration is in excess of their requirements. This hypoglycaemia is a major contributor in the failure to achieve glycaemic targets in Type 1 Diabetes. The Investigational Device is a non-invasive device designed to detect warning signs of hypoglycaemia. The device consists of a wrist band connected by a flexible wire to a ring. Parameters monitored by this device include wrist and finger tremor and temperature. The study aims to collect overnight exploratory data regarding the relationship of the above parameters to hypoglycaemia. Having a device that has the potential to provide an early warning of impending hypoglycaemia may have a positive impact upon the wellbeing of the person with Type 1 Diabetes.
Interventions
This study aims to obtain overnight exploratory data regarding the relationship of non-glycaemic parameters (such as wrist and finger tremor and temperature to hypoglycaemia) in Type 1 Diabetes participants. This study intends to evaluate the accuracy of a non-invasive device designed to detect these early signs of hypoglycaemia. The Investigational Device (ID) consists of a wrist band connected by a flexible wire to a ring. Participants will wear the ID overnight placed on the wrist and middle finger of the non-dominant hand prior to retiring to bed. The ID will be removed after the participant wakes in the morning. Parameters including wrist and finger tremor and temperature will be monitored continuously by the ID during wear. Following baseline assessment, participants will be provided with education regarding the ID. Participants will be instructed to undertake reference capillary blood glucose measurements (a minimum of 4 times a day over the 2 week study period) and to wear Continuous Glucose Monitoring (CGM) sensors for the two-week study duration. During the study, the participants will also be instructed to keep a diary documenting activity, diet, capillary glucose reading, insulin, and hypogylcaemic episodes. Participants will attend the Clinical Trials Centre (CTC) on Day 8 to have the CGM sensor changed. On Day 15, participants will attend the CTC for collection of the study devices and diary.
Sponsors
Study design
Eligibility
Inclusion criteria
-Type 1 Diabetes -HbA1c <9.0% -Participant willing to comply with study protocol
Exclusion criteria
-Diabetic ketoacidosis within the past 4 weeks -Pregnant or planned pregnancy during the study period -Dermatological conditions involving the region of glucose sensor insertion -Participant on beta-blocker therapy